How ImmunityBio is transforming cancer treatment - in just 30 seconds
“I think I'm blessed with truly the best team in all of pharma… we are doing something that's bigger than all of us!”
Interviews
Ocugen has a cure in sight
“The cost of gene therapies can reach millions of dollars per patient… Our goal is developing cost-effective treatments that can be accessible globally.”
Gene therapy in ophthalmology is on the cusp of a breakthrough
"One of our first patients was treated over five years ago. He had received 109 injections over 10 years, and five years after a single Ixo-Vec injection, he is free of injections with stable vision and no fluid in the eye."
CAR T-cell therapies beat blood cancer - can they do the same for autoimmune diseases?
CAR T-cell therapies are often lauded as one of the industry’s most important frontiers, and these therapies have seen amazing success in treating hematological cancers — will autoimmune diseases yield next?
How Seer is using proteomics to revolutionize how we understand complex diseases
Seer's Proteograph Product and Analysis suites are utilizing proprietary nanoparticle technology to help us understand diseases like never before. David Horn, President and CFO, tells us more.
This biotech is using the chromatin regulatory system to fight back against cancer
Foghorn Therapeutics recently announced dosing of the first patient in the Phase 1 trial of FHD-909 in collaboration with Eli Lilly.
Cell therapy used to be expensive, then Cellares changed everything
The CEO of Cellares sits down to tell us how the Cell Shuttle, an engineering marvel of 21st Century biotech, was invented and the lives that it could save...
Alphabet's Verily is the future of precision and public health
We spoke with Stephen Gillett, Alphabet’s health-tech boss on life, leadership and AI.
A deep dive into one of the fastest growing biotechs of all time
Avidity Biosciences has achieved successful data readouts for all three of its programs in Phase 1/2 clinical trials, initiated its first Phase 3 trial, and raised over $1.1 billion this year.
Inside the world’s most innovative square mile: MassBio leads the life sciences
Kendalle Burlin O’Connell tells us about the privilege of heading up MassBio - the organization that represents the extraordinary life sciences sector in Massachusetts.
How rationally designed therapeutics could revolutionize gene therapy
Gene therapy holds incredible promise, but the challenge has always been delivery - Affinia Therapeutics seeks to solve one of the most important problems that the industry faces.
This new blood test could change everything for immunocompromised patients
Alec Ford explains how the Karius Test® uses cutting-edge genomics to detect infections caused by more than 1,000 pathogens within a day of receiving a blood sample, offering a breakthrough for immunocompromised patients, particularly those with cancer.
What a 10 year mission to become a leading CRO looks like
Julie Ross took the helm of Advanced Clinical over a decade ago. Now, they are one of the largest private CROs in America, and have helped biotechs and pharma in 54 countries take their life-saving drugs from concept to clinic.
This startup could save big pharma millions of dollars using a new AI translatability platform
AI and drug discovery are multi-billion dollar markets, but money (and data) is wasted every year from a poor understanding and implementation of translatability from animal models to humans. Dr. Jo Varshney's BIOiSIM platform seeks to change that.
How big could the GLP-1 activator market be?
There is a huge boom in the newfound 'GLP-1 supplements' industry, and New Zealander CaloCurb is taking advantage, seeing 400% to 600% growth per quarter. They are now in the middle of their fourth, and largest, human trial - but will strong clinical results be enough to capture the market?
Opentrons, backed by SoftBank & Khosla, is bringing lab automation to the masses
It took little over 40 Opentrons robots to provide the majority of COVID-19 testing for the city of New York - 15 million people. Top-tier investors have piled in, will their bets pay off in 2025?